This review evaluated the effectiveness of transdermal nicotine patches, compared to placebo patches, in terms of smoking abstinence over one year The authors reported odds ratios of around 1.8, regardless of whether the endpoint was point-prevalence abstinence, continuous or sustained abstinence, or both. These conclusions appear appropriate given the evidence presented, but some relevant evidence was excluded.
Authors' objectives
To determine the effectiveness of transdermal nicotine patches compared to placebo patches, in terms of continuous or sustained abstinence from smoking over one year. 
Study selection
Randomised controlled trials (RCTs) comparing transdermal nicotine patches with placebo patches for smoking cessation were eligible for inclusion in the review. Included trials had to have at least one year of follow-up, have abstinence biochemically verified and report this outcome as an odds ratio.
Among included trials, the nicotine dosage administered via patch ranged from 5 to 30 mg/day and duration of treatment ranged from three to 18 weeks. In included trials, abstinence was validated by measuring either exhaled carbon monoxide or serum/saliva cotinine. Sustained, continuous and point prevalence abstinence outcomes were all included.
Two reviewers independently selected studies for inclusion, with disagreements resolved by discussion.
Assessment of study quality
Validity of the included studies was assessed according to the Jadad scale, which evaluates studies in terms of reporting of randomisation, blinding and withdrawals, resulting in a total score of between 0 and 5 points. Studies scoring 0 points were excluded from the meta-analysis.
The authors did not state how many reviewers performed the validity assessment.
Data extraction
Data were extracted on the proportion of participants abstaining at one year in each treatment group.
The authors did not state how many reviewers performed the extraction.
